Digital health has been all over the news in recent weeks. There have been announcements from Novo Nordisk and Noom, Abbott and Omada, Astellas and WellDoc, Orexo and GAIA, Ironwood and Pear Therapeutics, and many others. We have heard about Amazon deepening its footprint in healthcare, and Google's collaborations with Stanford Medicine, Cleveland Clinic and Mayo Clinic, as well as numerous other collaboration-based programs through Google's Verily and Google Fit.
In this executive panel, hear from industry leaders about lessons learned from implementing digital health alliances in their organizations:
Brooke Paige, CSAP
Former Vice President Alliance Management
Head of Healthcare Strategic Partnerships
Chris Lento is Head of Healthcare Strategic Partnerships for Noom. Noom is a digital health company focused on behavior change. Chris has 27+ years of healthcare experience and has held roles of increasing scope and responsibility in pharmaceuticals, biotechnology, healthcare technology and digital health. Chris has worked for the past several years helping groups such as: Pear Therapeutics and Palo Alto Health Sciences create and execute commercial go to market strategies. Chris also has a consulting practice helping healthcare organizations to build commercial strategy and launch execution. Chris serves on the Board of Trustees and Programming and Planning Committee for Maine Behavioral Health. He is passionate about improving the availability and quality of healthcare services and technology across the US.
Chris lives in Falmouth Maine with his wife Ann and (3) children Maggie, Collin and Molly. Chris is a passionate outdoorsman and enjoys activities such as skiing, cycling and hiking.
VP of Product
Fruit Street Health
Davina Pallone, VP of Product at Fruit Street Health, leverages over 20 years of experience as a product leader to empower teams to find valuable, creative, and engaging solutions to complex problems.
For the past seven years, Davina has focused on the intersection of science and software. At Fruit Street, she's building a platform to deliver both acute telemedicine care as well as chronic disease prevention and management programs. At Neurotrack, she leveraged international partnerships to launch a digital platform that combines scientifically-validated cognitive assessments with a personalized cognitive health intervention. Previously, Davina scaled the product platform at Pear Therapeutics, where big pharma alliances are key to developing and marketing FDA cleared, prescription digital therapeutics to treat people suffering from a range of serious diseases.
Davina holds a B.S. in Scientific and Technical Communications with a focus in Chemical Engineering from Michigan Technological University, and a B.A. in Fine Art from Westminster College.
Knut Sturmhoefel, CA-AM, PhD
Global Head Alliance Management
Novartis International AG
Knut is leading the Novartis Global Alliance Management, a team of seasoned alliance directors at Novartis Pharma, Oncology, Sandoz Biopharma, and NIBR. The team's vision is to ensure Novartis' partnering readiness by establishing a collaborative leadership system.
Knut joined Novartis in 2002, first in product development before taking on various roles in business development. Between 2008 and 2013, Knut managed the broad alliance portfolio of the ophthalmology and neuroscience franchises, including the highly successful alliance between Novartis and Genentech for Lucentis®. Between 2014 and 2019, Knut headed all BD&L efforts of the respiratory and ophthalmology franchises. His BD&L experience includes a wide range from identifying and assessing partnering opportunities, closing many deals of different structures and various complexity, managing long-term successful alliances across all life-cycle stages including blockbuster products, and being responsible for portfolio management in M&A transactions.
Knut has a broad background in research, development, and business. Prior to joining Novartis, he worked for over 12 years in the US. After starting his career in immunology and cancer research at the US National Institutes of Health and the German Cancer Research Center, he joined two biotech companies in the Boston area.